MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ekir.2026.106638

Медицинская библиотека · Kidney international reports · 2026

Kidney Survival in Children With Steroid-Resistant Nephrotic Syndrome Treated by Rituximab.

Chan Eugene Yu-Hin, Ho Irene Yuk-Ying, Au Chun-Ting, Yu Ellen L M, Angeletti Andrea, Banerjee Sushmita, Boyer Olivia, Chan Chang-Yien, Francis Anna, Ghiggeri Gian Marco, Hamada Riku, Hooman Nakysa, Hopf Luke Sydney, I Mohamad Ikram, Ijaz Iftikhar, Ivanov Dmytro D, Kang Hee Gyung, Lucchetti Laura, Lugani Francesca, Ma Alison Lap-Tak, Morello William, Pradhan Subal Kumar, Prikhodina Larisa, Raafat Reem H, Sinha Rajiv, Teo Sharon, Tomari Kouki, Vivarelli Marina, Webb Hazel, Yap Hui Kim, Yap Desmond Yat-Hin, Tullus Kjell

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Kidney outcomes in children with steroid-resistant nephrotic syndrome (SRNS) following rituximab remain unclear.

METHODS

We conducted an international retrospective cohort study across 23 centers in 17 countries, including children with SRNS who did not respond to calcineurin inhibitors (CNIs) and subsequently, received rituximab. Patients with genetic variants were excluded. The primary outcome was kidney survival.

RESULTS

We analyzed data on 151 children (53% males; median age at onset: 6.8 years; primary vs. secondary SRNS: 54% vs. 46%; focal segmental glomerulosclerosis [FSGS]: 62%). All subjects received CNIs before rituximab (0-3 months: 21%; 3-6 months: 26%; 6-12 months: 26%; > 12 months: 26%). Upon rituximab, 73 subjects (48%) had normal kidney function, 47 (31%) had chronic kidney disease (CKD)2, and 31 (21%) had CKD3. Twenty-eight (19%) developed kidney failure. Overall kidney survival was 82.7%, 75.8%, and 72.3% at 3, 5, and 7 years post-rituximab. Baseline CKD staging before rituximab was associated with kidney survival at 5 years (log-rank P < 0.001); CKD stage 1, 91.7%; CKD stage 2, 70.4%; and CKD stage 3, 35.5%). The predictive factors for inferior kidney survival were CKD2 (adjusted hazard ratio [HRadj]: 2.7, 95% confidence interval [CI]: 1.5-4.9, P < 0.001), lower baseline serum albumin (log-rank P = 0.01; HRadj: 0.88, 95% CI: 0.81-0.95; P < 0.001) and FSGS (log-rank P = 0.03; HRadj: 3.4, 95% CI: 1.1-10.0; P < 0.001). Nonremission at 6 months was associated with inferior kidney survival (61.2% at 5 years), compared with complete remission (CR) or partial remission (PR) (100% at 5 years) (log-rank P = 0.01; HRadj: 14.1, 95% CI: 2.2-93.5, P = 0.01). Duration of prior calcineurin inhibition and SRNS type were not significant predictors.

CONCLUSION

Kidney survival of SRNS following add-on rituximab is 70% to 80% over 3 to 7 years. Nonresponse, preexisting CKD, lower albumin, and FSGS predict inferior kidney survivals.

Для цитирования: Chan Eugene Yu-Hin, Ho Irene Yuk-Ying, Au Chun-Ting, Yu Ellen L M, Angeletti Andrea, Banerjee Sushmita, Boyer Olivia, Chan Chang-Yien, Francis Anna, Ghiggeri Gian Marco, Hamada Riku, Hooman Nakysa, Hopf Luke Sydney, I Mohamad Ikram, Ijaz Iftikhar, Ivanov Dmytro D, Kang Hee Gyung, Lucchetti Laura, Lugani Francesca, Ma Alison Lap-Tak, Morello William, Pradhan Subal Kumar, Prikhodina Larisa, Raafat Reem H, Sinha Rajiv, Teo Sharon, Tomari Kouki, Vivarelli Marina, Webb Hazel, Yap Hui Kim, Yap Desmond Yat-Hin, Tullus Kjell. Kidney Survival in Children With Steroid-Resistant Nephrotic Syndrome Treated by Rituximab.. Kidney international reports. 2026. DOI: 10.1016/j.ekir.2026.106638.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.